TD Cowen analyst Ritu Baral reiterated a Hold rating and $28.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

H.C. Wainwright cuts Sarepta (SRPT) price target to $0, reiterates Sell ratingJuly 21, 2025 6:42 AM Needham Downgrades Sarepta Therapeutics (SRPT) to UnderperformJuly 21, 2025 6:30 AM BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)July 21, 2025 6:03 AM Wells Fargo Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)July 21, 2025 5:50 AM Sarepta Therapeutics (SRPT) PT Lowered to $20 at JPMorganJuly 21, 2025 5:43 AM Sarepta Therapeutics (SRPT) options active amid large share price sell offJuly 21, 2025 5:23 AM BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)July 21, 2025 5:05 AM William Blair Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)July 21, 2025 5:04 AM Mizuho Downgrades Sarepta Therapeutics (SRPT) to NeutralJuly 21, 2025 4:33 AM Leerink Partners Downgrades Sarepta Therapeutics (SRPT) to Market PerformJuly 21, 2025 3:23 AM Deutsche Bank Downgrades Sarepta Therapeutics (SRPT) to SellJuly 21, 2025 3:21 AM ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPTJuly 19, 2025 2:17 PM Sarepta receives FDA request to halt ELEVIDYS shipments for some patientsJuly 18, 2025 8:10 PM Sarepta Therapeutics Provides Statement on ELEVIDYSJuly 18, 2025 7:39 PM Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty'July 18, 2025 2:19 PM ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPTJuly 18, 2025 2:11 PM FDA to Request Sarepta (SRPT) to Voluntarily Stop All Shipments of Elevidys - ReutersJuly 18, 2025 12:52 PM FDA Investigating Whether Sarepta's (SRPT) Elevidys Should Stay On The Market - BloombergJuly 18, 2025 12:09 PM Sarepta Therapeutics (SRPT) PT Lowered to $50 at BMO Capital Following Mangement CallJuly 18, 2025 12:04 PM SRPT Investors Have the Opportunity to Lead the Sarepta Securities Fraud Lawsuit with Faruqi & Faruqi, LLPJuly 18, 2025 11:46 AM Needham Downgrades Sarepta Therapeutics (SRPT) to HoldJuly 18, 2025 11:45 AM Sarepta Therapeutics (SRPT) CEO: did not disclose patient death on June 16 call as "It was neither material nor central to the topics at hand" - Conference CallJuly 18, 2025 10:43 AM Sarepta Therapeutics (SRPT) PT Lowered to $20 at BofA Securities, 'Safety reports could limit uptake of SRPT’s gene therapies'July 18, 2025 9:42 AM Morgan Stanley Reiterates Equalweight Rating on Sarepta Therapeutics (SRPT)July 18, 2025 9:33 AM Goldman Sachs Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)July 18, 2025 8:59 AM William Blair on Sarepta Therapeutics (SRPT): 'we continue to view the stock’s near-term upside potential as limited'July 18, 2025 8:58 AM Leerink Partners Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)July 18, 2025 8:55 AM Sarepta Therapeutics (SRPT) PT Lowered to $41 at OppenheimerJuly 18, 2025 8:34 AM Sarepta shares tumble after report of patient death in early-stage trialJuly 18, 2025 6:54 AM Sarepta Therapeutics (SRPT) PT Raised to $28 at TD CowenJuly 18, 2025 5:44 AM SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 17, 2025 4:02 PM Sarepta Therapeutics (SRPT) PT Lowered to $23 at RBC CapitalJuly 17, 2025 10:28 AM Sarepta Therapeutics (SRPT) PT Lowered to $32 at Piper SandlerJuly 17, 2025 10:24 AM Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)July 17, 2025 8:33 AM Needham Reiterates Buy Rating on Sarepta Therapeutics (SRPT)July 17, 2025 7:11 AM Sarepta Therapeutics (SRPT) PT Raised to $35 at BairdJuly 17, 2025 7:09 AM Sarepta Therapeutics (SRPT) PT Lowered to $65 at Wells FargoJuly 17, 2025 7:07 AM